BACKGROUND: Recurrent Clostridium difficile infection (CDI) with poor response to standard antimicrobial therapy is a growing medical concern. We aimed to investigate the outcomes of fecal microbiota transplant (FMT) for relapsing CDI using a frozen suspension from unrelated donors, comparing colonoscopic and nasogastric tube (NGT) administration. METHODS:Healthy volunteer donors were screened and a frozen fecal suspension was generated. Patients with relapsing/refractory CDI were randomized to receive an infusion of donor stools by colonoscopy or NGT. The primary endpoint was clinical resolution of diarrhea without relapse after 8 weeks. The secondary endpoint was self-reported health score using standardized questionnaires. RESULTS:A total of 20 patients were enrolled, 10 in each treatment arm. Patients had a median of 4 (range, 2-16) relapses prior to study enrollment, with 5 (range, 3-15) antibiotic treatment failures. Resolution of diarrhea was achieved in 14 patients (70%) after a single FMT (8 of 10 in the colonoscopy group and 6 of 10 in the NGT group). Five patients were retreated, with 4 obtaining cure, resulting in an overall cure rate of 90%. Daily number of bowel movements changed from a median of 7 (interquartile range [IQR], 5-10) the day prior to FMT to 2 (IQR, 1-2) after the infusion. Self-ranked health score improved significantly, from a median of 4 (IQR, 2-6) before transplant to 8 (IQR, 5-9) after transplant. No serious or unexpected adverse events occurred. CONCLUSIONS: In our initial feasibility study, FMT using a frozen inoculum from unrelated donors is effective in treating relapsing CDI. NGT administration appears to be as effective as colonoscopic administration. CLINICAL TRIALS REGISTRATION: NCT01704937.
RCT Entities:
BACKGROUND: Recurrent Clostridium difficileinfection (CDI) with poor response to standard antimicrobial therapy is a growing medical concern. We aimed to investigate the outcomes of fecal microbiota transplant (FMT) for relapsing CDI using a frozen suspension from unrelated donors, comparing colonoscopic and nasogastric tube (NGT) administration. METHODS: Healthy volunteer donors were screened and a frozen fecal suspension was generated. Patients with relapsing/refractory CDI were randomized to receive an infusion of donor stools by colonoscopy or NGT. The primary endpoint was clinical resolution of diarrhea without relapse after 8 weeks. The secondary endpoint was self-reported health score using standardized questionnaires. RESULTS: A total of 20 patients were enrolled, 10 in each treatment arm. Patients had a median of 4 (range, 2-16) relapses prior to study enrollment, with 5 (range, 3-15) antibiotic treatment failures. Resolution of diarrhea was achieved in 14 patients (70%) after a single FMT (8 of 10 in the colonoscopy group and 6 of 10 in the NGT group). Five patients were retreated, with 4 obtaining cure, resulting in an overall cure rate of 90%. Daily number of bowel movements changed from a median of 7 (interquartile range [IQR], 5-10) the day prior to FMT to 2 (IQR, 1-2) after the infusion. Self-ranked health score improved significantly, from a median of 4 (IQR, 2-6) before transplant to 8 (IQR, 5-9) after transplant. No serious or unexpected adverse events occurred. CONCLUSIONS: In our initial feasibility study, FMT using a frozen inoculum from unrelated donors is effective in treating relapsing CDI. NGT administration appears to be as effective as colonoscopic administration. CLINICAL TRIALS REGISTRATION: NCT01704937.
Authors: Ju Young Chang; Dionysios A Antonopoulos; Apoorv Kalra; Adriano Tonelli; Walid T Khalife; Thomas M Schmidt; Vincent B Young Journal: J Infect Dis Date: 2008-02-01 Impact factor: 5.226
Authors: Sarah P Preheim; Allison R Perrotta; Jonathan Friedman; Chris Smilie; Ilana Brito; Mark B Smith; Eric Alm Journal: Methods Enzymol Date: 2013 Impact factor: 1.600
Authors: Konstantinos Z Vardakas; Konstantinos A Polyzos; Konstantina Patouni; Petros I Rafailidis; George Samonis; Matthew E Falagas Journal: Int J Antimicrob Agents Date: 2012-03-06 Impact factor: 5.283
Authors: Matthew J Hamilton; Alexa R Weingarden; Michael J Sadowsky; Alexander Khoruts Journal: Am J Gastroenterol Date: 2012-01-31 Impact factor: 10.864
Authors: Eero Mattila; Raija Uusitalo-Seppälä; Maarit Wuorela; Laura Lehtola; Heimo Nurmi; Matti Ristikankare; Veikko Moilanen; Kimmo Salminen; Maaria Seppälä; Petri S Mattila; Veli-Jukka Anttila; Perttu Arkkila Journal: Gastroenterology Date: 2011-12-07 Impact factor: 22.682
Authors: Lawrence J Brandt; Olga C Aroniadis; Mark Mellow; Amy Kanatzar; Colleen Kelly; Tina Park; Neil Stollman; Faith Rohlke; Christina Surawicz Journal: Am J Gastroenterol Date: 2012-03-27 Impact factor: 10.864
Authors: Els van Nood; Anne Vrieze; Max Nieuwdorp; Susana Fuentes; Erwin G Zoetendal; Willem M de Vos; Caroline E Visser; Ed J Kuijper; Joep F W M Bartelsman; Jan G P Tijssen; Peter Speelman; Marcel G W Dijkgraaf; Josbert J Keller Journal: N Engl J Med Date: 2013-01-16 Impact factor: 91.245
Authors: Jessica R Allegretti; Monika Fischer; Sashidhar V Sagi; Matthew E Bohm; Hala M Fadda; Sejal R Ranmal; Shrish Budree; Abdul W Basit; Dean L Glettig; Eva L de la Serna; Amanda Gentile; Ylaine Gerardin; Sonia Timberlake; Rotem Sadovsky; Mark Smith; Zain Kassam Journal: Dig Dis Sci Date: 2018-12-05 Impact factor: 3.199
Authors: Christopher Staley; Matthew J Hamilton; Byron P Vaughn; Carolyn T Graiziger; Krista M Newman; Amanda J Kabage; Michael J Sadowsky; Alexander Khoruts Journal: Am J Gastroenterol Date: 2017-02-14 Impact factor: 10.864